| . | Myelofibrosis Patients . | Ruxolitinib Patients . |
|---|---|---|
| Clinical Characteristics | ||
| N | 6236 | 181 |
| Splenomegaly | 22% | 15% |
| Myeloid metaplasia | 45% | 14% |
| Thrombocytopenia | 22% | 9% |
| Laboratory Test Results | ||
| N | 583 | 90 |
| Hemoglobin <10 g/dL | 63% | 72% |
| Platelet count <50,000/microlitera | 22% | 18% |
| Platelet count <100,000/microliterb | 38% | 42% |
| Platelet count 100,000-200,000/microliterb | 48% | 57% |
| Platelet count >200,000/microliterb | 65% | 62% |
| . | Myelofibrosis Patients . | Ruxolitinib Patients . |
|---|---|---|
| Clinical Characteristics | ||
| N | 6236 | 181 |
| Splenomegaly | 22% | 15% |
| Myeloid metaplasia | 45% | 14% |
| Thrombocytopenia | 22% | 9% |
| Laboratory Test Results | ||
| N | 583 | 90 |
| Hemoglobin <10 g/dL | 63% | 72% |
| Platelet count <50,000/microlitera | 22% | 18% |
| Platelet count <100,000/microliterb | 38% | 42% |
| Platelet count 100,000-200,000/microliterb | 48% | 57% |
| Platelet count >200,000/microliterb | 65% | 62% |
aPossible thrombocytopenia
bAssociated with different dosing levels for ruxolitinib per FDA label.